AlphAIalphai — Financial news for AI agents
yahoo.comAUG 202 min read

Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies

Abbott Laboratories will pay $670 million to settle lawsuits alleging its preterm infant formula causes necrotizing enterocolitis. The settlement follows a $495 million judgment upheld by an appeals court. Abbott denies liability and faces 1,700 ongoing lawsuits involving 12,700 infants. The company maintains its products are safe.

Original reporting
yahoo.com
Published Aug 20, 2026, 11:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 12:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies — source image
Source · yahoo.com
Decision brief

The 30-second read

Med
01

Why it matters

The settlement resolves a major legal exposure but does not admit liability; investors will watch for any further litigation developments.

02

Market read

Legal settlement news for a large health‑care firm; short‑term price impact likely negative.

03

What to watch

Potential insurance recoveries or tax benefits from the settlement could mitigate net cost.

Relevance 8/10Novelty 8/10Timing: announcement day

Background

Abbott faces thousands of lawsuits alleging its preterm infant formula causes necrotizing enterocolitis (NEC).

Market effects

Sector

May increase scrutiny on infant‑nutrition segment and could affect peers like Mead Johnson.

Regional

U.S. health‑care sector could see slight pullback.

Global

Limited to companies with similar product lines; broader market impact minimal.

Counterpoint

What could challenge this read

Settlement may clear legal uncertainty, allowing long‑term confidence in Abbott's product line.

Key entities

  • Company
    Abbott Laboratories

    U.S. health‑care company settling litigation.

  • Individual
    Margo Gill

    Plaintiff whose case led to the $495 million judgment.

Read at source← All news

Related articles

AUG 20
$ABTLowAI 8/10

Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants

Abbott (NYSE: ABT) agreed to pay $670M to resolve litigation involving its preterm infant formulas, including the Gill case and claims for 2,000 infants. The company denies liability and maintains the safety of its products, supported by medical professionals and regulators. Pending lawsuits involve 12,700 infants. Abbott aims to resolve remaining cases.

prnewswire.com2 min
AUG 19
$ABTMedAI 8/10

Abbott settles appeal of $495 million infant formula verdict

Abbott Laboratories (ABT) settled an appeal of a $495 million verdict related to its infant formula, according to court documents. The 2024 jury ruling linked the formula to necrotizing enterocolitis (NEC) in a child. Over 1,000 similar lawsuits are pending against Abbott and Mead Johnson (Reckitt). The settlement terms were not disclosed. ABT and Reckitt deny their formulas cause NEC, emphasizing breast milk's protective benefits.

investing.com2 min
AUG 11
$ABTMed

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories shares rose about 1.2% in morning trading after the company announced a multi-year collaboration with Google Health. Abbott’s Lingo continuous glucose monitor data will be integrated into the Google Health app, with personalized coaching via Google Health Coach and a large real-world metabolic study. The move was driven by company-specific news amid a flat U.S. market.

investing.com3 min